A Phase 3, Randomized, Open-Label, Comparative Bridging Study of CAELYX Versus Topotecan HCl in Subjects With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2014
Price : $35 *
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Topotecan
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Xian-Janssen
- 04 Nov 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Aug 2013 Planned End Date changed from 1 Jan 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
- 01 Jun 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.